Cellectar Biosciences, Inc. (CLRB) Research

Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.

Market snapshot

Symbol
CLRB
Price
$2.79
Day change
+12.50%
Market cap
$8.9M
P/E ratio
-0.57x
52-week range
2.2-10.8
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$11.00

Recent news

  • What's Going With Cellectar Biosciences Stock On Wednesday?

    Cellectar Biosciences Inc (NASDAQ:CLRB) shares are down during Wednesday's premarket session after the stock closed almost 12% higher on Tuesday after positive clinical trial data and financing efforts.

  • Cellectar Biosciences Stock Rallies As Blood Cancer Data Impresses

    Cellectar Biosciences, Inc. (NASDAQ:CLRB) shares are up during Tuesday's trading session as the company announced promising results from its Phase 2b CLOVER WaM clinical trial.

Peer companies

  • AEON Biopharma, Inc. (AEON)
  • Bolt Biotherapeutics, Inc. (BOLT)
  • Cingulate Inc. (CING)
  • Evogene Ltd. (EVGN)
  • Imunon, Inc. (IMNN)
  • Lyra Therapeutics, Inc. (LYRA)
  • Mustang Bio, Inc. (MBIO)
  • Marker Therapeutics, Inc. (MRKR)

Recent insider activity

  • Gu Andrew — trade (0 shares) on 2026-05-18
  • Longcor Jarrod — P-Purchase (26040 shares) on 2026-05-07
  • Longcor Jarrod — P-Purchase (8680 shares) on 2026-05-07
  • CARUSO JAMES V — P-Purchase (26040 shares) on 2026-05-07
  • CARUSO JAMES V — P-Purchase (8680 shares) on 2026-05-07

Open Cellectar Biosciences, Inc. (CLRB) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.